Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14637585 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLCTSBPAX8 | |
| SCHEMBL13043257 | 0.97 | CTSK (0.56) | CTSKCTSSCTSLCTSBPAX8 | |
| SCHEMBL969253 | 0.95 | PAX8 (0.53) | CTSKCTSSCTSLCTSBPAX8 | |
| SCHEMBL18978665 | 0.94 | CTSK (0.53) | CTSKCTSSCTSLCTSBPAX8 | |
| SCHEMBL14684989 | 0.91 | CTSK (0.51) | CTSKCTSSCTSLCTSBPAX8 | |
| SCHEMBL18978668 | 0.91 | CTSK (0.51) | CTSKCTSSCTSLCTSBPAX8 | |
| SCHEMBL7922903 | 0.91 | PAX8 (0.51) | CTSKCTSSCTSLCTSBPAX8 | |
| SCHEMBL10241805 | 0.90 | CTSK (0.53) | CTSKCTSSCTSLCTSBAKT1 | |
| SCHEMBL13702233 | 0.89 | ACE (0.59) | CTSKCTSSCTSLCTSBPAX8 | |
| SCHEMBL16908988 | 0.89 | ACE (0.59) | CTSKCTSSCTSLCTSBPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047284-A1 | METHOD FOR THE PREPARATION OF LISDEXAMFETAMINE | FERMION OY (FI) | 2026-03-05 | — | — | WO | disclosed |
| US-20250206698-A1 | Process for Making Lisdexamfetamine Dimesylate | Pharmapotheca A, Inc. | 2025-06-26 | — | — | US | disclosed |
| US-10927068-B2 | Process for preparing acylated amphetamine derivatives | SpecGx LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-10544434-B2 | Process for the preparation of lisdexamfetamine and related derivatives | NORAMCO, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190161435-A1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC | 2019-05-30 | — | — | US | disclosed |
| EP-1644019-B2 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017098533-A2 | PROCESS FOR PREPARATION OF LISDEXAMPHETAMINE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-15 | — | — | WO | disclosed |
| WO-2013011526-A1 | PROCESS FOR PREPARATION OF LISDEXAMPHETAMINE AND SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2013-01-24 | — | — | WO | disclosed |
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | BLUE OWL CAPITAL CORPORATION, AS NEW AGENT | 2012-07-26 | — | — | US | disclosed |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20090131334-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131332-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131326-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131325-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131533-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| US-7375083-B2 | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080086016-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-7223735-B2 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | PNMT, COMT, DDT | CTSK 2605/4885CTSS 2232/4885CTSL 2361/4885 |
| US-20250206698-A1 | Process for Making Lisdexamfetamine Dimesylate | COMT, MGAM, ADH5 | CTSK 1729/4885CTSS 1273/4885CTSL 2009/4885 |
| US-20090131533-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSK 1897/4885CTSS 1737/4885CTSL 1445/4885 |
| US-10544434-B2 | Process for the preparation of lisdexamfetamine and related derivatives | COMT, MGAM, GAA | CTSK 1847/4885CTSS 1154/4885CTSL 1811/4885 |
| US-10927068-B2 | Process for preparing acylated amphetamine derivatives | COMT, DOT1L, AASDHPPT | CTSK 1452/4885CTSS 1847/4885CTSL 940/4885 |
| US-20090131332-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSK 1897/4885CTSS 1737/4885CTSL 1445/4885 |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | COMT, CYP3A5, CYP2D6 | CTSK 1897/4885CTSS 1737/4885CTSL 1445/4885 |
| US-20090131326-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSK 1897/4885CTSS 1737/4885CTSL 1445/4885 |
| US-20190161435-A1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | COMT, DOT1L, AASDHPPT | CTSK 1452/4885CTSS 1847/4885CTSL 940/4885 |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSK 1897/4885CTSS 1737/4885CTSL 1445/4885 |
| US-20090131325-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSK 1897/4885CTSS 1737/4885CTSL 1445/4885 |
| US-20080086016-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | COMT, KDM6B, KDM5B | CTSK 578/4885CTSS 904/4885CTSL 950/4885 |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSK 1897/4885CTSS 1737/4885CTSL 1445/4885 |
| US-20090131334-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSK 1897/4885CTSS 1737/4885CTSL 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.